A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

Poveda, A; Oaknin, A; Romero, I; Guerrero-Zotano, A; Farinas-Madrid, L; Rodriguez-Freixinos, V; Mallol, P; Lopez-Reig, R; Lopez-Guerrero, JA

Poveda, A (corresponding author), Hosp Quironsalud Valencia, Oncogynecol Dept, Initia Oncol, Avda Blasco Ibanez 14, Valencia 46010, Spain.

SCIENTIFIC REPORTS, 2021; 11 (1):

Abstract

The poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity in patients with ovarian or breast cancer with or without BRCA......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索